Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO #ADAP #Adaptimmune #Biotechnology #Celltherapy #Chemicals #ESMO23 #HealthCare #Investing #NASDAQ #Oncology

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers75% response rate in ovarian, urothelial, and head & neck cancers in patients who received three or fewer prior lines of therapyAcceptable benefit-to-risk profile with ADP-A2M4CD8 next-generation monotherapy and in combination with the checkpoint...


http://dlvr.it/Sxq3gX

Comments

Popular posts from this blog

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Coelacanth Announces Q3 2023 Financial and Operating Results #CEI.CA #CEI.V #CEIEF #Earnings #Investing #OTC #OTCMarkets #OTCStocks #Oil #OilAndGas #QuarterlyResults #Results #SmallCaps #TSXV

Aurora Solar Technologies Corporate Update #AACTF #ACU.CA #ACU.V #AlternativeEnergy #AuroraSolarTech #CleanEnergy #CorporateUpdate #Energy #Investing #OTC #OTCMarkets #OTCStocks #RenewableEnergy #SmallCaps #Solar #TSXV